Complex IV subunit 1 defect predicts postoperative survival in hepatocellular carcinoma

Le,Puo‑Hsien; Huang,Shih‑Chiang; Lim,Siew‑Na; Chou,Chang‑Hua; Yeh,Ta‑Sen; Chen,Tse‑Ching; Yen,Tzung‑Hai; Su,Ming‑Yao; Chiu,Cheng‑Tang; Yeh,Chau‑Ting; Lin,Wey‑Ran

doi:10.3892/ol.2014.1966

Complex IV subunit 1 defect predicts postoperative survival in hepatocellular carcinoma

Authors:
- Puo‑Hsien Le
- Shih‑Chiang Huang
- Siew‑Na Lim
- Chang‑Hua Chou
- Ta‑Sen Yeh
- Tse‑Ching Chen
- Tzung‑Hai Yen
- Ming‑Yao Su
- Cheng‑Tang Chiu
- Chau‑Ting Yeh
- Wey‑Ran Lin
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan, R.O.C., Department of Pathology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan, R.O.C., Department of Neurology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan, R.O.C., Department of General Surgery, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan, R.O.C., Department of Nephrology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan, R.O.C., Liver Research Center, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan, R.O.C.
Published online on: March 11, 2014 https://doi.org/10.3892/ol.2014.1966
Pages: 1430-1438

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitochondrial oxidative phosphorylation (OXPHOS) is responsible for adenosine triphosphate synthesis and OXPHOS deficiency plays a significant role in tumorigenesis. The defects of mitochondrial‑encoded OXPHOS subunits have been found in normal and cirrhotic liver, however their contributions in hepatocellular carcinoma (HCC) are not clear. The present study aimed to examine these defects in resected HCC tissues. In total, 102 human HCC tissues were collected from patients undergoing curative resection, and immunohistochemical staining was performed to assess tissue expression of complex I subunit 6, complex III subunit 3, complex IV subunit 1 (CIV‑1) and complex V subunit 6. Cox proportional hazard model analysis was performed, including all clinicopathological factors, to postoperatively estimate the overall survival rate. The results showed that the majority of HCC tissues contained various degrees of expression defects for OXPHOS subunits. Among these, the major CIV‑1 defect (expression defect area of >25% of the examined area) (P<0.001) and early distant metastasis (P<0.001) were independently associated with the overall survival rate. Kaplan‑Meier analysis also demonstrated that the major CIV‑1 defect was significantly associated with a poor overall survival rate (log‑rank, P=0.002). The findings in the present study clearly indicate that the major CIV‑1 expression defect may serve as an independent negative prognostic factor in HCC patients following curative resection.

View Figures

View References

1	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar
2	Sherman M: Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 30:3–16. 2010. View Article : Google Scholar
3	Marra M, Sordelli IM, Lombardi A, et al: Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 9:1712011. View Article : Google Scholar : PubMed/NCBI
4	Shen HM and Ong CN: Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mut Res. 366:23–44. 1996. View Article : Google Scholar : PubMed/NCBI
5	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
6	Llovet JM, Schwartz M and Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 25:181–200. 2005. View Article : Google Scholar : PubMed/NCBI
7	Hoshida Y, Villanueva A, Kobayashi M, et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 359:1995–2004. 2008. View Article : Google Scholar : PubMed/NCBI
8	Imamura H, Matsuyama Y, Tanaka E, et al: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 38:200–207. 2003. View Article : Google Scholar
9	Chau GY, Wu CW, Lui WY, et al: Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg. 231:552–558. 2000. View Article : Google Scholar
10	Hsu YC, Fu HH, Jeng YM, Lee PH and Yang SD: Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J Clin Oncol. 24:3780–3788. 2006. View Article : Google Scholar
11	Kitamoto M, Nakanishi T, Kira S, et al: The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer. 72:1859–1865. 1993. View Article : Google Scholar
12	Kobayashi T, Kubota K, Takayama T and Makuuchi M: Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg. 181:284–288. 2001. View Article : Google Scholar
13	Poon RT, Lau CP, Ho JW, Yu WC, Fan ST and Wong J: Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res. 9:5339–5345. 2003.
14	Poon RT, Ng IO, Lau C, et al: Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 233:227–235. 2001. View Article : Google Scholar
15	Tsujita E, Taketomi A, Gion T, et al: Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma. Oncology. 69:342–347. 2005. View Article : Google Scholar : PubMed/NCBI
16	Uenishi T, Kubo S, Yamamoto T, et al: Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 94:851–857. 2003. View Article : Google Scholar : PubMed/NCBI
17	Yeh CT, So M, Ng J, et al: Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology. 52:1922–1933. 2010. View Article : Google Scholar
18	Schapira AH: Mitochondrial disease. Lancet. 368:70–82. 2006. View Article : Google Scholar : PubMed/NCBI
19	Warburg O: The Metabolism of Tumors. Arnold Constable; London: pp. 254–270. 1930
20	Maynard S, Schurman SH, Harboe C, de Souza-Pinto NC and Bohr VA: Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis. 30:2–10. 2009. View Article : Google Scholar : PubMed/NCBI
21	Croteau DL and Bohr VA: Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. J Biol Chem. 272:25409–25412. 1997. View Article : Google Scholar : PubMed/NCBI
22	Wallace DC: A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 39:359–407. 2005. View Article : Google Scholar
23	Brandon M, Baldi P and Wallace DC: Mitochondrial mutations in cancer. Oncogene. 25:4647–4662. 2006. View Article : Google Scholar
24	Chatterjee A, Mambo E and Sidransky D: Mitochondrial DNA mutations in human cancer. Oncogene. 25:4663–4674. 2006. View Article : Google Scholar : PubMed/NCBI
25	Lee HC and Wei YH: Mitochondrial DNA instability and metabolic shift in human cancers. Int J Mol Sci. 10:674–701. 2009. View Article : Google Scholar : PubMed/NCBI
26	Poyton RO and McEwen JE: Crosstalk between nuclear and mitochondrial genomes. Annu Rev Biochem. 65:563–607. 1996. View Article : Google Scholar
27	Chandra D and Singh KK: Genetic insights into OXPHOS defect and its role in cancer. Biochim Biophys Acta. 1807:620–625. 2011. View Article : Google Scholar : PubMed/NCBI
28	Mayr JA, Meierhofer D, Zimmermann F, et al: Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res. 14:2270–2275. 2008. View Article : Google Scholar : PubMed/NCBI
29	Dasgupta S, Hoque MO, Upadhyay S and Sidransky D: Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res. 68:700–706. 2008. View Article : Google Scholar : PubMed/NCBI
30	Bonora E, Porcelli AM, Gasparre G, et al: Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res. 66:6087–6096. 2006. View Article : Google Scholar
31	Namslauer I, Dietz MS and Brzezinski P: Functional effects of mutations in cytochrome c oxidase related to prostate cancer. Biochim Biophys Acta. 1807:1336–1341. 2011. View Article : Google Scholar
32	Bernstein C, Facista A, Nguyen H, et al: Cancer and age related colonic crypt deficiencies in cytochrome c oxidase I. World J Gastrointest Oncol. 2:429–442. 2010. View Article : Google Scholar : PubMed/NCBI
33	Lee HC, Li SH, Lin JC, Wu CC, Yeh DC and Wei YH: Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res. 547:71–78. 2004. View Article : Google Scholar
34	Yin PH, Lee HC, Chau GY, et al: Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer. 90:2390–2396. 2004.PubMed/NCBI
35	Yin PH, Wu CC, Lin JC, Chi CW, Wei YH and Lee HC: Somatic mutations of mitochondrial genome in hepatocellular carcinoma. Mitochondrion. 10:174–182. 2010. View Article : Google Scholar : PubMed/NCBI
36	Greaves LC, Reeve AK, Taylor RW and Turnbull DM: Mitochondrial DNA and disease. J Pathol. 226:274–286. 2012. View Article : Google Scholar
37	Müller-Höcker J, Aust D, Rohrbach H, et al: Defects of the respiratory chain in the normal human liver and in cirrhosis during aging. Hepatology. 26:709–719. 1997.
38	Shah SA, Cleary SP, Wei AC, et al: Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 141:330–339. 2007. View Article : Google Scholar : PubMed/NCBI
39	Theise ND, Curado MP, Franceschi S, et al: WHO classification of tumours of the digestive system. Hepatocellular Carcinoma. Bosman FT, Carneiro F, Hruban RH and Theise ND: 4th edition. IARC Press; Lyon: pp. 205–216. 2010
40	Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP and Burroughs AK: A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 20:325–339. 2013.PubMed/NCBI
41	Edge SE, Byrd DR, Compton CC, et al: AJCC Cancer Staging Manual and Handbook. 7th ed. Springer; New York, NY, USA: 2010
42	Srinivasan S and Avadhani NG: Cytochrome c oxidase dysfunction in oxidative stress. Free Radic Biol Med. 53:1252–1263. 2012. View Article : Google Scholar : PubMed/NCBI
43	Arnold S: The power of life - cytochrome c oxidase takes center stage in metabolic control, cell signalling and survival. Mitochondrion. 12:46–56. 2012. View Article : Google Scholar
44	Schägger H and Pfeiffer K: The ratio of oxidative phosphorylation complexes I–V in bovine heart mitochondria and the composition of respiratory chain supercomplexes. J Biol Chem. 276:37861–37867. 2001.
45	Acín-Pérez R, Fernández-Silva P, Peleato ML, Pérez-Martos A and Enriquez JA: Respiratory active mitochondrial supercomplexes. Mol Cell. 32:529–539. 2008.
46	Acín-Pérez R, Bayona-Bafaluy MP, Fernández-Silva P, et al: Respiratory complex III is required to maintain complex I in mammalian mitochondria. Mol Cell. 13:805–815. 2004.PubMed/NCBI
47	Schäfer E, Seelert H, Reifschneider NH, Krause F, Dencher NA and Vonck J: Architecture of active mammalian respiratory chain supercomplexes. J Biol Chem. 281:15370–15375. 2006.
48	Brown MD, Yang CC, Trounce I, Torroni A, Lott MT and Wallace DC: A mitochondrial DNA variant, identified in Leber hereditary optic neuropathy patients, which extends the amino acid sequence of cytochrome c oxidase subunit I. Am J Hum Genet. 51:378–385. 1992.
49	Varlamov DA, Kudin AP, Vielhaber S, et al: Metabolic consequences of a novel missense mutation of the mtDNA CO I gene. Hum Mol Genet. 11:1797–1805. 2002. View Article : Google Scholar : PubMed/NCBI
50	Lucioli S, Hoffmeier K, Carrozzo R, Tessa A, Ludwig B and Santorelli FM: Introducing a novel human mtDNA mutation into the Paracoccus denitrificans COX I gene explains functional deficits in a patient. Neurogenetics. 7:51–57. 2006. View Article : Google Scholar
51	Karadimas CL, Greenstein P, Sue CM, et al: Recurrent myoglobinuria due to a nonsense mutation in the COX I gene of mitochondrial DNA. Neurology. 55:644–649. 2000. View Article : Google Scholar : PubMed/NCBI
52	Pandya A, Xia XJ, Erdenetungalag R, et al: Heterogenous point mutations in the mitochondrial tRNA Ser(UCN) precursor coexisting with the A1555G mutation in deaf students from Mongolia. Am J Hum Genet. 65:1803–1806. 1999. View Article : Google Scholar
53	Greaves LC, Preston SL, Tadrous PJ, et al: Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc Natl Acad Sci USA. 103:714–719. 2006. View Article : Google Scholar : PubMed/NCBI
54	Namslauer I and Brzezinski P: A mitochondrial DNA mutation linked to colon cancer results in proton leaks in cytochrome c oxidase. Proc Natl Acad Sci USA. 106:3402–3407. 2009. View Article : Google Scholar : PubMed/NCBI
55	Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar
56	Rindi G, Arnold R, Bosman FT, et al: Nomenclature and classification of neuroendocrine neoplasms of the digestive system. WHO Classification of Tumours of the Digestive System. Bosman TF, Carneiro F, Hruban RH and Theise ND: 4th ed. International Agency for Research on Cancer (IARC); Lyon, France: pp. 132010